CO6640224A2 - Inhibidores de la actividad de la proteína tirosina quinasa - Google Patents

Inhibidores de la actividad de la proteína tirosina quinasa

Info

Publication number
CO6640224A2
CO6640224A2 CO12207317A CO12207317A CO6640224A2 CO 6640224 A2 CO6640224 A2 CO 6640224A2 CO 12207317 A CO12207317 A CO 12207317A CO 12207317 A CO12207317 A CO 12207317A CO 6640224 A2 CO6640224 A2 CO 6640224A2
Authority
CO
Colombia
Prior art keywords
tyrosine kinase
inhibitors
kinase protein
protein activity
compounds
Prior art date
Application number
CO12207317A
Other languages
English (en)
Inventor
Yohei Yuki
Masashi Kishida
Arkadii Vaisburg
Franck Raeppel
Stephane Raeppel
Stephen Claridge
Lijie Zhan
Frederic Gaudette
Michael Mannion
Norifumi Sato
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of CO6640224A2 publication Critical patent/CO6640224A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa. En particular, la invención se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa de los receptores de los factores de crecimiento, lo que da como resultado la inhibición de la señalización del receptor, por ejemplo, la inhibición de la señalización del receptor del VEGF (factor de crecimiento endotelial vascular). La invención también proporciona compuestos, composiciones y métodos para el tratamiento de enfermedades y condiciones de proliferación de células y enfermedades, desordenes o condiciones oftálmicas.
CO12207317A 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa CO6640224A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16

Publications (1)

Publication Number Publication Date
CO6640224A2 true CO6640224A2 (es) 2013-03-22

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
CO12207310A CO6630193A2 (es) 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
CO12207317A CO6640224A2 (es) 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO12207310A CO6630193A2 (es) 2010-04-16 2012-11-15 Inhibidores de la actividad de la proteína tirosina quinasa seleccionada

Country Status (18)

Country Link
US (3) US8455484B2 (es)
EP (2) EP2563795A4 (es)
JP (2) JP2013523846A (es)
KR (2) KR20130058006A (es)
CN (2) CN103025740B (es)
AR (2) AR080871A1 (es)
AU (2) AU2011241420B2 (es)
CA (2) CA2796008A1 (es)
CO (2) CO6630193A2 (es)
EA (2) EA201291052A1 (es)
MX (2) MX2012012032A (es)
MY (1) MY157319A (es)
NZ (2) NZ602954A (es)
SG (2) SG184882A1 (es)
TW (2) TW201204735A (es)
UA (1) UA108878C2 (es)
WO (2) WO2011127565A1 (es)
ZA (2) ZA201207482B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
AU2009221583B2 (en) * 2008-03-05 2013-06-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CN103025740B (zh) * 2010-04-16 2015-07-01 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) * 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
AU2005266803B2 (en) * 2004-07-30 2011-10-27 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610382A2 (pt) * 2005-05-20 2010-06-15 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
EP2183255A4 (en) * 2007-08-29 2011-06-15 Methylgene Inc METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CONDENSED HETEROCYCLIC KINASE INHIBITORS
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
AU2009221583B2 (en) 2008-03-05 2013-06-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CN103025740B (zh) * 2010-04-16 2015-07-01 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
AU2011241422B2 (en) 2015-05-07
US20110257175A1 (en) 2011-10-20
NZ602948A (en) 2014-09-26
CN103025740B (zh) 2015-07-01
CO6630193A2 (es) 2013-03-01
AU2011241420B2 (en) 2015-04-16
US20110257100A1 (en) 2011-10-20
CA2796008A1 (en) 2011-10-20
JP2013523846A (ja) 2013-06-17
AR080875A1 (es) 2012-05-16
AR080871A1 (es) 2012-05-16
US20140315801A1 (en) 2014-10-23
ZA201207482B (en) 2013-09-25
CA2796054A1 (en) 2011-10-20
MX2012012032A (es) 2012-12-17
WO2011127565A1 (en) 2011-10-20
JP2013525286A (ja) 2013-06-20
EP2563794A4 (en) 2013-12-04
CN102947315A (zh) 2013-02-27
EP2563795A4 (en) 2013-10-23
ZA201207557B (en) 2013-06-26
NZ602954A (en) 2014-11-28
TW201204734A (en) 2012-02-01
EP2563795A1 (en) 2013-03-06
KR20130100234A (ko) 2013-09-10
UA108878C2 (ru) 2015-06-25
MX2012012031A (es) 2012-12-17
CN103025740A (zh) 2013-04-03
EA201291055A1 (ru) 2013-09-30
WO2011127567A1 (en) 2011-10-20
KR20130058006A (ko) 2013-06-03
EA201291052A1 (ru) 2013-04-30
SG184882A1 (en) 2012-11-29
US8906852B2 (en) 2014-12-09
SG184883A1 (en) 2012-11-29
AU2011241422A1 (en) 2012-11-01
MY157319A (en) 2016-05-31
TW201204735A (en) 2012-02-01
EP2563794A1 (en) 2013-03-06
US8455484B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
CO6640224A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa
CO6290684A2 (es) Inhibidores de actividad de proteina tirosina quinasa
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY35249A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
CR20170478A (es) Compuestos novedosos
CR20150490A (es) Derivados de piridina como inhibidores de la quinasa reorganizada durante la transfección (ret)
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
MX2020009849A (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
DOP2014000253A (es) Inhibidores del nampt
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
CR20150029A (es) Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular

Legal Events

Date Code Title Description
FG Application granted